A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
Marcia Hall, Hakim‐Moulay Dehbi, Susana Banerjee, Rosemary Lord, Andrew R. Clamp, Jonathan A. Ledermann, Shibani Nicum, Rachel Lilleywhite, Rebecca Bowen, Agnieszka Michael, A Feeney, Rosalind Glasspool, Allan Hackshaw, Gordon Rustin
Topics & Concepts
MedicineNintedanibInternal medicinePlaceboHazard ratioClinical endpointAdverse effectGastroenterologyNeutropeniaCyclophosphamideBevacizumabSurgeryRandomized controlled trialChemotherapyConfidence intervalIdiopathic pulmonary fibrosisLungAlternative medicinePathologyOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyAngiogenesis and VEGF in Cancer